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Abstract
Aims/hypothesis Negative effects on the progression of
adenocarcinomas by hyperinsulinaemia and the insulin
analogue glargine (A21Gly,B31Arg,B32Arg human in-
sulin) have recently been suggested. Most actions of this
insulin analogue have hitherto been explained by direct
stimulation of growth potential of neoplastic cells and
by its IGF-1 related properties. However, insulin-
stimulated angiogenesis could be an additional factor
involved in tumour progression and clinical outcomes
associated with cancer.
Methods Five types of human adenocarcinoma (breast,
colon, pancreas, lung and kidney) were evaluated for the
presence of insulin receptors (IRs) on angiogenic structures.
In an in vitro angiogenesis assay, various commercially
available insulin compounds were evaluated for their
potential to increase capillary-like tube formation of human
microvascular endothelial cells (hMVEC). Insulin com-
pounds used were: human insulin, insulin lispro (B28Lys,
B29Pro human insulin), insulin glargine and insulin detemir
(B29Lys[e-tetradecanoyl],desB30 human insulin).
Results Insulin receptors were found to be strongly
expressed on the endothelium of microvessels in all
evaluated adenocarcinomas, in addition to variable
expression on tumour cells. Low or no detectable
expression of IRs was seen on microvessels in extra-
tumoral stroma. Incubation with commercially available
insulin compounds increased capillary-like tube forma-
tion of hMVEC in vitro.
Conclusions/interpretation Our results suggest that all
tested insulin compounds may stimulate tumour growth
by enhancing local angiogenesis. Future studies need to
confirm the association between insulin therapy in type 2
diabetes and tumour progression.
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Abbreviations
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Introduction
Recent retrospective studies suggest that patients with type
2 diabetes who use the insulin analogue insulin glargine
(A21Gly,B31Arg,B32Arg human insulin) might have an
increased risk of developing cancer. Hemkens et al. found a
positive association between daily insulin dosage and the
incidence of malignant neoplasms. Interestingly, this asso-
ciation was present for human insulin and insulin analogues
such as glargine, lispro (B28Lys,B29Pro human insulin)
and aspart (B28Asp human insulin). Moreover, after
adjusting for insulin dose, they found a dose-dependently
increased risk of cancer in patients treated with insulin
glargine compared with patients treated with human insulin
with an adjusted hazard ratio of 1.31 (95% CI 1.20–1.42)
for a daily dose of 50 IU [1]. In another report, Jonasson et
al. mentioned that patients taking insulin glargine had an
almost twofold increased risk of breast cancer compared
with patients using other types of insulin [2]. The SDRN
Epidemiology Group observed a similarly increased risk,
but attributed this to an allocation bias [3]. A study by
Currie et al. showed no association between insulin
analogues and cancer progression as compared with human
insulin, but did show that patients using any kind of insulin
had a higher risk of developing adenocarcinomas than those
on metformin [4].
An important point to elucidate in this context is the
pathophysiological mechanism through which insulin could
be involved in tumour progression. In their editorial
accompanying the above-mentioned articles, Smith and
Gale [5] noted that it is surprising that these studies were
able to detect differences in cancer rates after only a few
years of insulin exposure, because cancer takes many years
to develop. Supported by existing literature, they suggest
that, if insulin does indeed influence cancer incidence, this
is possibly due to stimulatory effects on pre-existing
malignant foci rather than to de-novo carcinogenesis.
Insulin is known to augment mitogenesis and proliferation
of distinctive cell types and its effect can be mediated
through insulin receptors (IRs), insulin like growth factor-1
(IGF-1) receptors (IGF-1Rs) or hybrid IR-IGF-1Rs. IRs and
IGF-1Rs are frequently present on pre-existing tumour cells
and this could give insulin a molecular pathway to
contribute to tumour expansion [5]. However, we recently
showed that IRs are also abundantly present on angiogenic
structures in human atherosclerotic plaques suggesting a
biological role of insulin on local angiogenesis [6].
Furthermore, it has been shown that insulin is involved in
angiogenesis during wound healing [7]. We therefore
hypothesised that such a mechanism might also be involved
in tumour expansion and tumour growth.
We analysed whether IRs are expressed on angiogenic
structures in adenocarcinomas. In addition, we evaluated
the effect of commercially available human insulin and
insulin analogues on capillary-like tube formation of human
microvascular endothelial cells (hMVEC) in vitro.
Methods
Collection of specimens Tissue was obtained from archival
material of resection specimens in accordance with guide-
lines set out by the ‘Code for Proper Secondary Use of
Human Tissue’ of the Dutch Federation of Biomedical
Scientific Societies. Included were adenocarcinomas from
breast (n=15), colon (n=15), pancreas (n=15), lung (n=15)
and kidney (n=15). As a control, we investigated peri-
tumoural parenchyma of the included specimens, especially
of those known to be insulin-sensitive (kidney and
pancreas).
Immunohistochemical analysis All specimens were rou-
tinely fixed in buffered formalin and embedded in paraffin.
After heat-induced epitope retrieval in Tris-EDTA pH9.0
(20 min at 98°C), anti-IR β-subunit antibody (1 μg/ml,
60 min, room temperature; Millipore/Chemicon, Temecula,
CA, USA) and anti-IGF1-R α-subunit antibody (0.5 μg/ml,
60 min, room temperature; Millipore/Chemicon) were
immunostained using a three-step polymer detection system
(ImmunoLogic, Duiven, the Netherlands). Horseradish-
peroxidase activity was visualised in brown with diamino-
benzidine (DAB+; Dako, Glostrup, Denmark). Negative
controls consisted of concentration-matched isotype con-
trols (Dako).
Expression of IRs on endothelial and epithelial cells
within adenocarcinoma and in surrounding tissue was
assessed using a semi-quantitative score: 0=no IR expres-
sion, 1=minimal IR expression, 2=moderate IR expression,
3=strong IR expression.
Immuno double-staining combining anti-IR antibody in
red (Vector Red; Vector Laboratories, Burlingame, CA,
USA) and anti-CD31 (Dako) antibody in blue (Vector Blue)
was performed with the sequential double alkaline phos-
phatase method [8].
Spectral imaging Analysis of double staining slides was
performed with spectral imaging using a multispectral
imaging system (Nuance VIS-FL; Cambridge Research
Instrumentation, Woburn, MA, USA). Data sets were
acquired from 420–72 nm at 20 nm intervals. Spectral
library of single-Vector Red and single-Vector Blue was
used to unmix the double staining into the individual
components. Using Nuance software version 2.8 (Cam-
bridge Research Instrumentation), an exclusive image of
IR/CD31 co-localisation as well as fluorescent-like pseudo-
coloured images were created [9].
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In vitro angiogenesis Individual human foreskin MVEC
(hMVEC), obtained from three different donors, were
confluently seeded in M199 supplemented with 10%
(vol./vol.) heat-inactivated human serum and 10% (vol./
vol.) newborn calf serum on a three-dimensional fibrin
matrix, prepared with 2 mg/ml fibrinogen (Calbiochem, La
Jolla, CA, USA) and 0.1 U/ml thrombin (Organon, Boxtel,
the Netherlands), as previously described [10]. To study the
effect of different insulin compounds and IGF-1 on
capillary-like tube formation, hMVEC were stimulated with
10 ng/ml basic fibroblast growth factor (bFGF) (Peprotech,
London, UK) and 10 ng/ml TNF-α (Sigma Aldrich, St
Louis, MO, USA) in absence or presence of 1×10−9, 1×
10−8 or 1×10−6mol/l of human insulin (actrapid), short-
acting insulin analogue (insulin lispro), long-acting insulin
analogues (insulin detemir [B29Lys(e-tetradecanoyl),
desB30 human insulin], insulin glargine) or IGF-1 (GroPep,
Adelaide, Australia) in triplicate or quadruplicate. Medium
was refreshed every other day. After 7 to 12 days of
incubation, the formation of tubular structures was analysed
by phase contrast microscopy and quantified with Optimas
image analysis software (Media Cybernetics, Bethesda,
MD, USA). The use of hMVEC was approved by the
ethical committee of the VU University Medical Centre,
Amsterdam, the Netherlands.
Statistical analysis Semi-quantitative expression data were
compared by means of the Wilcoxon matched-pairs signed-
ranks test. Results from the in vitro angiogenesis experi-
ments were combined and are presented as mean ± SEM.
Statistical differences were determined by a paired t test,
using Prism 4 (GraphPad, San Diego, CA, USA). p<0.05
was considered to be statistically significant.
Results
Presence of insulin receptors (immunohistochemical
evaluation) The endothelium of microvessels in the tumour
Fig. 1 Immunohistochemical staining for the insulin receptor in colon
(a), breast (b) and renal (c) adenocarcinoma (magnification ×400).
Tumour cells are variably positive (*), whereas neovessels in the
tumour stroma are invariably strongly positive (arrows). Double-
staining (magnification ×200) demonstrates colocalisation (purple,
arrows) for the IR (red) and CD31 (blue) in neovessels in the tumour
stroma in breast (d) and kidney carcinoma (g), which was confirmed
by spectral imaging analysis for breast (e, f) and kidney (h, i)
carcinoma respectively, with colocalisation in magenta/yellow. d, g
Endothelial cells in the surrounding non-tumour stroma show no or
very little IR staining (*) compared with endothelial cells in the
tumour stroma (**)
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stroma of all examined tumour types was consistently and
strongly positive for the IR, with much reduced or absent
staining in the microvasculature of surrounding non-tumour
stroma and parenchymal tissue, including that of insulin-
sensitive tissues (kidney and pancreas; Fig. 1). The endothelial
nature of this staining pattern was confirmed by double
immunohistochemistry for the IR and CD31, aided by spectral
imaging analysis. In addition, all tumour types showed
variably cytoplasmic and/or membranous staining on epithe-
lial cells for the IR, ranging from none to strong expression.
Staining intensity was scored semi-quantitatively, show-
ing a clear significant increased staining in tumour micro-
vessels as compared with microvessels in non-tumour
stroma for all tumour types. The pattern for epithelial
staining was more complex and revealed more intensive
staining in the parenchyma for most tumour types com-
pared with the neoplastic epithelium (Fig. 2). Staining for
IGF-1R was weak on endothelial cells, with no differences
between tumour and non-tumour tissue (data not shown).
Capillary-like tube formation (in vitro experiments) Figure 3
shows the combined results of five to eight in vitro
experiments, in which the effect of insulin compounds on
capillary-like tube formation of hMVEC in 3D fibrin
matrices was assessed. Compared with stimulation with
bFGF and TNF-α alone (control), addition of distinctive
insulin compounds (1×10−9, 1×10−8 and 1×10−6mol/l) to
the incubation medium led to significant increased
capillary-like tube formation of hMVEC. The extent of
capillary-like tube formation varied between compounds,
ranging from a 1.6- to 2.3-fold increase compared with
control. Stimulation with IGF-1 (1×10−9, 1×10−8 and 1×
10−6mol/l) gave a similar increase in capillary-like tube
formation (data not shown).
Discussion
This study suggests that distinctive insulin compounds
(exceeding a certain daily dose) could contribute to tumour
growth by enhancing local angiogenesis, possibly parallel
to the established direct mitogenic and proliferative effects
of insulin on tumours [5].
Our observations showed that common adenocarcino-
mas, which frequently afflict patients with type 2 diabetes,
contain large numbers of neovessels and that these vessels
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Fig. 2 Mean score of semi-
quantitative insulin receptor ex-
pression on (a) endothelial cells
and (b) epithelial cells in tumour
(T) vs surrounding parenchyma
(P). Scores: 0=no, 1=minimal,
2=moderate, 3=strong IR
expression. n=15 for each
tumour type; **p<0.01,
***p<0.001 and †p=0.02
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Fig. 3 Increased capillary-like tube formation by hMVEC after
stimulation with different insulin compounds. Black bar, control; light
grey bars, human insulin; mid-grey bars, insulin lispro; dark grey bars,
insulin detemir; white bars, insulin glargine. All human insulin
compounds enhanced, to varying degrees, capillary-like tube forma-
tion compared with stimulation with bFGF/TNF-α alone. Each
experiment was done in triplicate or quadruplicate. n=5 for 1×10−9
mol/l, n=8 for 1×10−8mol/l and 1×10−6mol/l insulin; *p<0.05 and
**p<0.01 compared with control
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abundantly express IRs, independent of tumour type. This
indicates that local expression of IR on neovessels is a
rather general phenomenon in the process of tumour
angiogenesis and that high volumes of exogenous insulin
could have side effects. Stimulation of these receptors with
insulin could promote angiogenesis and subsequent tumour
progression. It should be noted that tumours can have high
expression of hybrid receptors and particularly of the IR-A
isotype, which is not readily detectable with currently
available antibodies. Therefore, the IR expression detected
may be an underestimate.
The effect of insulin on angiogenesis has been observed
before. Liu et al. [7] recently reported that insulin stimulates
hMVEC migration and two-dimensional Matrigel tube
formation exclusively through the IR. Our in vitro experi-
ments showed that not only the long-acting insulin
analogue glargine enhances capillary-like tube formation,
but also all other evaluated insulin compounds. Hence,
insulin glargine is not an exclusive candidate for an
assumed relationship between increased tumour growth
and insulin use in patients with type 2 diabetes.
It is likely that the added insulin at high concentrations
may act via both IRs and IGF-1Rs. This might be the case
for insulin concentrations of 1×10−6 and 1×10−8, but not
for 1×10−9mol/l. Moreover, differences in capillary-like
tube formation between insulin detemir and insulin glargine
were not found. It is known that insulin glargine has a much
higher affinity for the IGF-1R compared with insulin
detemir [11]. Therefore, involvement of the IGF-1R
becomes less probable. Furthermore, since we found
increased IR expression and no increased IGF-1R expres-
sion on microvessels within adenocarcinomas, we assume
that in vivo the insulin × IR interactions are likely to be of
paramount importance for insulin-mediated angiogenic
effects in adenocarcinomas.
We would have preferred to use human tumour-derived
endothelial cells, instead of foreskin-derived hMVEC for
our in vitro experiments. However, to our knowledge, no
published reports describe the isolation and long-term
culturing of endothelial cells from human tumour tissue.
Since endothelial cells within tumour tissue are of benign
origin and adenocarcinomas normally contain much fibrin,
we consider our in vitro angiogenesis assay, which looks at
tube formation of benign hMVEC into a three-dimensional
fibrin matrix, to be appropriate.
In short, the current results suggest that insulin and
insulin analogues play a biological role in tumour growth
by stimulating local IRs with a subsequent increase in
angiogenesis. Without any doubt, additional prospective
studies will be required in order to confirm a possible
relationship between insulin therapy and tumour progres-
sion either by direct effects of insulin on tumour growth or
stimulation of local angiogenesis.
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